Literature DB >> 29456046

The spectrum of "off" in Parkinson's disease: What have we learned over 40 years?

Kelvin L Chou1, Mark Stacy2, Tanya Simuni3, Janis Miyasaki4, Wolfgang H Oertel5, Kapil Sethi6, Hubert H Fernandez7, Fabrizio Stocchi8.   

Abstract

The terms "on" and "off" were used by Marsden and his contemporaries over 40 years ago to describe times when Parkinson's disease patients experienced good motor function ("on") and immobility ("off"). Yet there remains no published consensus definition of "off", leading clinicians and patients to develop individualized impressions of "off" determinations. In this paper, we first discuss the evolution of the terminology and understanding of "off" states since Marsden's time, which now include non-motor as well as motor symptoms. We then review pathophysiology and risk factors for the development of "off" states as well as tools to detect the "off" state, before proposing a practical definition of "off" for consideration. A common, practical definition of the "off" state could improve clinical recognition of "off" symptoms and lead to significant benefit for patients.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Motor complications; Motor fluctuations; Non-motor fluctuations; Off; Parkinson's disease; Wearing off

Mesh:

Substances:

Year:  2018        PMID: 29456046     DOI: 10.1016/j.parkreldis.2018.02.001

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  42 in total

Review 1.  Old Drugs, New Delivery Systems in Parkinson's Disease.

Authors:  Harsh V Gupta; Kelly E Lyons; Rajesh Pahwa
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

2.  Evaluation of preoperative efficacy of levodopa in subthalamic deep brain stimulation.

Authors:  Wen Liu; Xiumin Zhang; Pan Nie; Lidao Chen; Kai Fu; Jibo Zhang; Jincao Chen; Jie Zhang
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

3.  Assessment of Wearing Off in Parkinson's disease using objective measurement.

Authors:  Parisa Farzanehfar; Holly Woodrow; Malcolm Horne
Journal:  J Neurol       Date:  2020-09-15       Impact factor: 4.849

4.  Update on the diagnosis and management of Parkinson's disease.

Authors:  Christopher Kobylecki
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

5.  Subthalamic nucleus deep brain stimulation improves dyskinesias in Parkinson's disease beyond levodopa reduction.

Authors:  James M Mossner; Parag G Patil; Kelvin L Chou
Journal:  J Neural Transm (Vienna)       Date:  2019-09-07       Impact factor: 3.575

6.  The Most Bothersome Aspects of Off Periods Reported by Individuals with Parkinson's Disease.

Authors:  Lana M Chahine; Briana Edison; Margaret Daeschler; Sneha Mantri; Steven Kahl; Robyn Rapoport; Arina Goyle; Chelle Precht; Catherine Kopil; Connie Marras
Journal:  Mov Disord Clin Pract       Date:  2020-03-05

Review 7.  Understanding, Impact, and Communication of "Off" Periods in Parkinson's Disease: A Scoping Review.

Authors:  Tara Rastgardani; Melissa J Armstrong; Anna R Gagliardi; Connie Marras
Journal:  Mov Disord Clin Pract       Date:  2018-10-09

8.  Patient Preferences for Treating "OFF" Episodes in Parkinson's Disease: A Discrete Choice Experiment.

Authors:  Andrew Thach; Jessie Sutphin; Joshua Coulter; Colton Leach; Eric Pappert; Carol Mansfield
Journal:  Patient Prefer Adherence       Date:  2021-06-01       Impact factor: 2.711

9.  The Experience of OFF Periods in Parkinson's Disease: Descriptions, Triggers, and Alleviating Factors.

Authors:  Sneha Mantri; Madeline Lepore; Briana Edison; Margaret Daeschler; Catherine M Kopil; Connie Marras; Lana M Chahine
Journal:  J Patient Cent Res Rev       Date:  2021-07-19

10.  Precisely timed dopamine signals establish distinct kinematic representations of skilled movements.

Authors:  Alexandra Bova; Matt Gaidica; Amy Hurst; Yoshiko Iwai; Julia Hunter; Daniel K Leventhal
Journal:  Elife       Date:  2020-11-27       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.